The main market opportunities in the Australian legal cannabis sector are driven by supportive regulatory frameworks, increased medical cannabis prescriptions, and a rising demand for low-dose CBD products. Domestic production and diversified product offerings further enhance growth, positioning Australia as a key cannabis innovation hub.
The Australia Legal Cannabis Market was valued at USD 126.32 million in 2024 and is expected to reach USD 420.33 million by 2030, rising at a CAGR of 22.16%
This growth is fueled by progressive legislative developments, increasing medical awareness, and broader access initiatives for therapeutic cannabis. Federal and state-level regulatory advancements are fostering a more organized and transparent cannabis sector.
The market is experiencing a notable rise in medical cannabis prescriptions, driven by its application in treating chronic pain, anxiety, sleep disorders, and other conditions. Domestic production is also gaining traction as companies invest in localized cultivation and processing infrastructure, aiming to enhance supply chain efficiency and reduce reliance on imports. Support from healthcare providers, coupled with growth in clinical education and research, continues to boost adoption across medical fields. Meanwhile, the industry is evolving through diversification in product offerings – such as oils, capsules, and topicals – and the integration of digital health platforms, positioning Australia as a key regional hub for cannabis innovation and export.
Favorable Regulatory Environment and Policy Support
A supportive regulatory framework and comprehensive policy measures are key enablers of growth in the Australia Legal Cannabis Market. Since the 2016 legalization of medicinal cannabis, the Australian government has implemented structured systems allowing licensed cultivation, production, and distribution. Agencies like the Therapeutic Goods Administration (TGA) and the Office of Drug Control (ODC) oversee pathways such as the Special Access Scheme (SAS) and the Authorised Prescriber Scheme, facilitating legal, controlled patient access to cannabis treatments when conventional methods fall short.
Recent developments, including the reclassification of low-dose CBD as a Schedule 3 substance, reflect a progressive stance aimed at increasing accessibility. Though no products have yet gained OTC approval, this shift highlights the government’s intent to broaden access to non-psychoactive cannabis applications. These changes not only enhance patient reach but also encourage foreign investment, support pharmaceutical innovation, and elevate Australia’s standing as a regulated and export-ready cannabis market.
High Costs of Production and Patient Access
The Australia Legal Cannabis Market faces significant hurdles due to the high costs associated with producing pharmaceutical-grade cannabis and the barriers these costs create for patient access. Compliance with strict quality and safety standards necessitates large investments in advanced cultivation technology and quality assurance systems. These costs inflate retail prices, placing a financial burden on patients – particularly since medical cannabis is not covered under the Pharmaceutical Benefits Scheme (PBS).
As a result, patients must rely on out-of-pocket payments, limiting affordability and reducing uptake, especially among those needing ongoing treatment. The lack of insurance coverage further exacerbates the issue. Additionally, navigating regulatory processes such as the SAS and securing prescriptions from qualified practitioners can be complex and time-consuming. Limited awareness among medical professionals about cannabis therapies adds to access difficulties. Together, these financial and procedural barriers hinder the market’s growth potential and restrict the widespread adoption of cannabis-based treatments.
Surge in Demand for Low-Dose CBD and OTC Access
A growing consumer interest in wellness and plant-based alternatives is fueling demand for low-dose cannabidiol (CBD) products in the Australian market. This trend gained momentum after the Therapeutic Goods Administration (TGA) reclassified low-dose CBD (up to 150 mg/day) as a Schedule 3 substance, potentially allowing over-the-counter availability without a prescription.
While no such products have yet received approval, the regulatory shift signals expanded access to cannabis-derived wellness products aimed at managing mild ailments like anxiety and sleep disorders. This evolving preference is prompting companies to invest in the research and development of clinically validated, standardized formulations that comply with strict safety and efficacy guidelines. As consumers increasingly favor self-directed health solutions, the market is witnessing heightened innovation and competition among players aiming to secure a share in this emerging OTC segment.
About ResearchAndMarkets.com ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
